Price$198.99-31.67 (-13.73%)
2026-04-142026-07-17
News · 26 weeks41+40%
2026-01-252026-07-19
Mix2290d
- Insider6(27%)
- Other6(27%)
- SEC Filings4(18%)
- Analyst3(14%)
- Earnings2(9%)
- Leadership1(5%)
Latest news
25 items- ANALYSTResMed downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $234.00
- ANALYSTResMed downgraded by Citigroup with a new price targetCitigroup downgraded ResMed from Buy to Neutral and set a new price target of $235.00
- INSIDERChairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)4 - RESMED INC (0000943819) (Issuer)
- SECResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure8-K - RESMED INC (0000943819) (Filer)
- PRResmed Announces Agreement to Sell MatrixCare BusinessSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-
- SECSEC Form 144 filed by ResMed Inc.144 - RESMED INC (0000943819) (Subject)
- PRResmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: https://investor.resmed.comDate: Thursday, August 6, 2026Time: 1:30 p.m. PT / 4:30 p.m. ETInternational: London, Thursday, August 6, 2026, 9:30 p.m. BST Sydney, Friday
- ANALYSTResMed downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded ResMed from Overweight to Equal-Weight and set a new price target of $230.00
- INSIDERChairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)4 - RESMED INC (0000943819) (Issuer)
- INSIDERGlobal General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)4 - RESMED INC (0000943819) (Issuer)
- PRAngelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 millionNoctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit
- PRResmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health PortfolioSAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders. The acquisition expands Resmed's clinical sleep health portfolio into an adjacent area of significant unmet need — the treatment of Restless Legs Syndrome (RLS), the third most prevalent sleep disorder.1,2 For Noctrix Health, joining Resmed brings an opportunity to scale its innovation, expand patient access, and accelerate impact fo
- SECSEC Form SD filed by ResMed Inc.SD - RESMED INC (0000943819) (Filer)
- PRResmed Announces Participation in the 46th Annual William Blair Growth Stock ConferenceSAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days. About ResmedResmed (
- PRResmed and ŌURA Partner to Expand Access to Sleep Health Education and CareSAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world's leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health. Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care. At the same time, the use of wearable technology to trac
- INSIDERChairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)4 - RESMED INC (0000943819) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bloomer Aaron3 - RESMED INC (0000943819) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Sandercock Brett4 - RESMED INC (0000943819) (Issuer)
- SECSEC Form 8-K filed by ResMed Inc.8-K - RESMED INC (0000943819) (Filer)
- PRResmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as SuccessorSAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor. "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat
- SECResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - RESMED INC (0000943819) (Filer)
- PRResmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%GAAP income from operations increased 17%; non-GAAP income from operations up 18%GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2026.
- ANALYSTAnalyst initiated coverage on ResMedAnalyst initiated coverage of ResMed with a rating of Overweight
- INSIDERSEC Form 4 filed by Farrell Michael J.4 - RESMED INC (0000943819) (Issuer)
- INSIDERSEC Form 4 filed by Sandercock Brett4 - RESMED INC (0000943819) (Issuer)
RMD FAQ
7 questionsWhat does ResMed Inc. do?
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the...Where does RMD stock trade?
ResMed Inc. (RMD) is listed on NYSE.What sector and industry is RMD in?
ResMed Inc. operates in the Health Care sector, Medical/Dental Instruments industry.Does RMD pay a dividend?
RMD's most recent ex-dividend date was 2026-05-14 with a cash dividend of $0.60 per share. No future ex-date is on file yet.What are analysts saying about RMD?
ResMed Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform on 2026-07-16.What companies are similar to RMD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare RMD side-by-side with any of them on Quantisnow.How can I track RMD on Quantisnow?
Quantisnow aggregates ResMed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RMD to receive live email and push alerts on every new disclosure.